Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

Tonix in the News

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
The Frederick News-Post | Oct 18, 2021

New Infectious Disease Research and Development Center Opens in Frederick

WDVM News | Oct 18, 2021

Tonix Pharmaceuticals comes to Frederick

Bloomberg | Aug 23, 2021

FDA Grants Full Approval of Pfizer-BioNTech Vaccine (Podcast)

Boston Business Journal | Aug 9, 2021

Biopharma company Tonix expanding to New Bedford

Boston Globe | Aug 2, 2021

Talking Points: N.J. biotech plans to manufacture vaccines in new Mass. plant

Baltimore Business Journal | Jul 27, 2021

New Jersey pharma company to purchase Frederick R&D facility

Benzinga | Jul 15, 2021

More Than Vaccines: Tonix Programs Address the Spectrum of Covid-19 Problems from Prevention, to Infection to Post-Viral Syndrome

Technology Networks | Jun 1, 2021

Dr. Seth Lederman discusses T Cell Immunity and COVID-19 on Technology Networks

Bloomberg | May 25, 2021

Dr. Seth Lederman Discusses COVID-19 Vaccine durability and further development on Bloomberg Radio

Bloomberg | Mar 23, 2021

Dr. Seth Lederman interviewed on Nobel Laureate Economist on Vaccine Equity

Benzinga | Mar 19, 2021

Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia

Benzinga | Feb 2, 2021

Tonix Pharmaceuticals CEO Believes That Additional COVID-19 Vaccine Research Is Still Needed

ABC FOX Montana | Jan 6, 2021

Dr. Seth Lederman interviewed on ABC FOX Montana to discuss highlights of Tonix’s planned vaccine manufacturing facility in Hamilton, MT

Contagion Live | Dec 4, 2020

Dr. Seth Lederman interviewed on Contagion Live to discuss its COVID-19 vaccine in development

Bloomberg | Jun 9, 2020

Dr. Seth Lederman interviewed on Bloomberg Radio to discuss COVID-19 Vaccine development

Technology Networks | Apr 7, 2020

Dr. Seth Lederman’s interview with the Science Writer for Technology Networks

New England Journal of Medicine | Mar 30, 2020

Developing Covid-19 Vaccines at Pandemic Speed

Proactive | Sep 5, 2019

Tonix Pharmaceuticals doses first patient in Phase 1 trial to treat PTSD

Washington Examiner | Jan 1, 2019

Military-related PTSD: Our year to act

Washington Post | Jul 7, 2017

Scientists synthesize smallpox cousin in ominous breakthrough

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.